Analysis and Development of Antigen-specific T Cells Derived from Peripheral Blood Mononuclear Cells of Healthy Donors

Anticancer Res. 2024 Apr;44(4):1377-1387. doi: 10.21873/anticanres.16934.

Abstract

Background/aim: Adoptive cell therapy using antigen-specific T cells is a promising treatment modality for cancer patients. Various methods to isolate specific T cells and identify corresponding T cell receptor (TCR) sequences are known. This study aimed to identify antigen-specific TCR from T cells isolated using carboxyfluorescein succinimidyl ester (CFSE), which marks proliferating activated T cells.

Materials and methods: CFSE stained healthy donor peripheral blood mononuclear cells (PBMCs) were treated with cytomegalovirus (CMV) or Epstein-Barr virus (EBV) peptides for seven days. Then, proliferating T cells with decreased CFSE staining were isolated and single cell VDJ sequencing was performed on isolated T cells to identify antigen-specific TCRs.

Results: As antigen-specific TCR candidates, ten TCR clones were selected for the CMV antigen and five for the EBV antigen. The reactivity of ten CMV TCR-transduced T cells and one EBV TCR-transduced T cell toward T2 cells pulsed with CMV or EBV peptide was confirmed via NFAT-luciferase, IFN-γ ELISA, and cytotoxicity assays.

Conclusion: Identification of antigen-specific TCRs with CFSE staining is a valid method for the development of effective immunotherapy. The identified CMV- or EBV-specific TCRs can be used for adoptive cell therapy to treat cancer.

Keywords: CMV; EBV; T cell receptor; TCR-T; cancer; cell therapy.

MeSH terms

  • Cytomegalovirus
  • Cytomegalovirus Infections*
  • Epstein-Barr Virus Infections* / therapy
  • Fluoresceins*
  • Herpesvirus 4, Human
  • Humans
  • Leukocytes, Mononuclear
  • Neoplasms*
  • Receptors, Antigen, T-Cell
  • Succinimides*
  • T-Lymphocytes

Substances

  • 5-(6)-carboxyfluorescein diacetate succinimidyl ester
  • Receptors, Antigen, T-Cell
  • Fluoresceins
  • Succinimides